STOCK TITAN

Femasys announces COO retirement and files separation agreement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Femasys Inc. (FEMY) announced the planned retirement of Chief Operating Officer Daniel Currie, effective December 15, 2025. He will continue in his current role until his departure.

Carrie’s retirement follows more than 20 years with the company, having joined in March 2004, and is attributed to personal health considerations and a desire to focus on family. In connection with the transition, the company and Mr. Currie entered into a Separation and General Release Agreement on October 16, 2025, filed as Exhibit 10.1. Femasys expressed appreciation for his leadership and service.

Positive

  • None.

Negative

  • None.

Insights

COO retirement disclosed with transition and separation agreement.

Femasys reported that COO Daniel Currie will retire effective December 15, 2025, remaining in role until then. The company and Mr. Currie executed a Separation and General Release Agreement on October 16, 2025, indicating a planned and documented transition.

The filing cites personal health and family reasons and recognizes over 20 years of service. No compensation or operational changes are detailed in the excerpt, so business impact cannot be assessed from these disclosures.

Subsequent filings may provide additional transition details or any interim leadership plans, if applicable.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549



FORM 8-K



CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 13, 2025



Femasys Inc.
(Exact name of Registrant as specified in its charter)



Delaware
001-40492
11-3713499
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

3950 Johns Creek Court, Suite 100
Suwanee, GA 30024
(770) 500-3910
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
FEMY
Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc. (the “Company”) informed the Company of his decision to retire from the Company, effective as of December 15, 2025. Mr. Currie will remain in his current role with the Company until his departure.

Mr. Currie’s decision to retire follows more than 20 years of dedicated service, having joined the Company in March 2004, and is based on personal health considerations, a desire to focus on family and the next chapter of his life.

In connection with his planned retirement, on October 16, 2025, the Company and Daniel Currie entered into a Separation and General Release Agreement (the “Separation Agreement”).

Under the terms of the Separation Agreement:

Any outstanding equity awards will be treated as follows: unvested stock options will vest through the retirement date.

Health benefits will continue under COBRA through December 31, 2026, with Company contributions consistent with current coverage levels.

The Separation Agreement includes a general release of claims, as well as non-competition, non-solicitation, and confidentiality covenants customary for such agreements.

The Company and Board of Directors extend their sincere appreciation to Mr. Currie for his more than 20 years of leadership and service and wish him the very best in his retirement.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Description
10.1

Separation Agreement
104

Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Femasys Inc.




By:
/s/ Kathy Lee-Sepsick


Names: Kathy Lee-Sepsick


Title: Chief Executive Officer



Date: October 17, 2025





FAQ

What did Femasys (FEMY) announce in this 8-K?

Femasys disclosed that COO Daniel Currie will retire effective December 15, 2025, and will remain in his role until that date.

Why is Femasys COO Daniel Currie retiring?

The company states Mr. Currie’s retirement is based on personal health considerations and a desire to focus on family.

Did Femasys enter an agreement related to the COO’s retirement?

Yes. Femasys and Mr. Currie entered into a Separation and General Release Agreement on October 16, 2025 (filed as Exhibit 10.1).

Will Daniel Currie remain at Femasys before retiring?

Yes. He will remain in his current role until his departure on December 15, 2025.

What is the exhibit associated with this Femasys 8-K?

Exhibit 10.1 is the Separation and General Release Agreement with Daniel Currie.

Does the filing detail compensation terms of the Separation Agreement?

The excerpt notes the agreement but does not detail its terms.
FEMASYS INC

NASDAQ:FEMY

FEMY Rankings

FEMY Latest News

FEMY Latest SEC Filings

FEMY Stock Data

46.78M
53.56M
11.3%
14.09%
2.81%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
SUWANEE